Cf. Morris et al., INTRAGRAFT EXPRESSION OF CYTOKINE TRANSCRIPTS DURING PIG PROISLET XENOGRAFT REJECTION AND TOLERANCE IN MICE, The Journal of immunology, 154(5), 1995, pp. 2470-2482
The rejection of pig proislet (islet precursor) xenografts in CBA/H mi
ce is a CD4(+) T cell-dependent process. The molecular mechanisms of x
enograft rejection, xenograft survival during anti-CD4 mAb therapy and
xenograft tolerance post-withdrawal of anti-CD4 mAb administration, w
ere examined by using a semiquantitative PCR method. Temporal analysis
of intragraft cytokine mRNA demonstrated a Th0-like pattern of expres
sion (IL-2, IFN-gamma, IL-3, IL-4, IL-5, and IL-10) on day 4 of the ac
ute xenograft rejection process. From day 5, however, only Th2-associa
ted transcripts (IL-3, IL-4, IL-5, and IL-10) were enhanced in xenogra
fts compared with isograft controls. Immunohistochemistry showed that
the principal participants in the rejection infiltrate were CD4(+) T c
ells and eosinophils, with smaller numbers of CD8(+) T cells. In vivo
depletion of CD4(+) T cells prevented xenograft rejection but had mini
mal effect on the peak levels of IL-2, IFN-gamma, and IL-10 mRNA; in c
ontrast, the enhanced expression of IL-3, IL-4, and IL-5 transcripts s
een in rejecting xenografts was abrogated. This established a positive
correlation between acute xenograft rejection, presence of CD4(+) T c
ells, and enhanced intragraft expression of mRNA for the Th2-type cyto
kines IL-3, IL-4, and IL-5. In tolerant hosts, long-term proislet xeno
graft survival and function (>190 days) was accompanied by intragraft
expression of IL-2 and IL-10 mRNA; IFN-gamma, IL-3, IL-4, and IL-5 mRN
A were either undetected or not enhanced. The induced rejection of lon
g-term functioning xenografts (>170 days) in nontolerant hosts resulte
d in selective enhancement of IL-4 transcript expression. This study s
uggests that Th2-like CD4(+) T cells are differentially activated in r
esponse to xenoantigen and that xenograft tolerance is associated with
lack of expression of the Th2 cytokine, IL-4.